1. Home
  2. BTAI vs NDLS Comparison

BTAI vs NDLS Comparison

Compare BTAI & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • NDLS
  • Stock Information
  • Founded
  • BTAI 2017
  • NDLS 1995
  • Country
  • BTAI United States
  • NDLS United States
  • Employees
  • BTAI N/A
  • NDLS N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • NDLS Restaurants
  • Sector
  • BTAI Health Care
  • NDLS Consumer Discretionary
  • Exchange
  • BTAI Nasdaq
  • NDLS Nasdaq
  • Market Cap
  • BTAI 8.3M
  • NDLS 35.4M
  • IPO Year
  • BTAI 2018
  • NDLS 2013
  • Fundamental
  • Price
  • BTAI $1.79
  • NDLS $0.72
  • Analyst Decision
  • BTAI Buy
  • NDLS Strong Buy
  • Analyst Count
  • BTAI 5
  • NDLS 2
  • Target Price
  • BTAI $34.60
  • NDLS $3.00
  • AVG Volume (30 Days)
  • BTAI 291.8K
  • NDLS 198.4K
  • Earning Date
  • BTAI 08-05-2025
  • NDLS 08-06-2025
  • Dividend Yield
  • BTAI N/A
  • NDLS N/A
  • EPS Growth
  • BTAI N/A
  • NDLS N/A
  • EPS
  • BTAI N/A
  • NDLS N/A
  • Revenue
  • BTAI $1,852,000.00
  • NDLS $495,670,000.00
  • Revenue This Year
  • BTAI $5.03
  • NDLS $5.37
  • Revenue Next Year
  • BTAI $291.01
  • NDLS $0.68
  • P/E Ratio
  • BTAI N/A
  • NDLS N/A
  • Revenue Growth
  • BTAI 5.47
  • NDLS N/A
  • 52 Week Low
  • BTAI $1.17
  • NDLS $0.55
  • 52 Week High
  • BTAI $21.92
  • NDLS $1.83
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 62.90
  • NDLS 36.25
  • Support Level
  • BTAI $1.59
  • NDLS $0.76
  • Resistance Level
  • BTAI $2.22
  • NDLS $0.82
  • Average True Range (ATR)
  • BTAI 0.21
  • NDLS 0.06
  • MACD
  • BTAI 0.04
  • NDLS -0.00
  • Stochastic Oscillator
  • BTAI 75.00
  • NDLS 4.80

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

Share on Social Networks: